Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

ENZN earnings analysis

Filed August 3, 2026 · Our reading of the company's report

The latest report

Viskase reported Q2 2026 revenue of $90.131 million, down 7.3% year over year, with temporary restructuring-related production constraints driving a $10.9 million volume decline. Gross margin was 12.3%, broadly near the…

Read full summary

Viskase reported Q2 2026 revenue of $90.131 million, down 7.3% year over year, with temporary restructuring-related production constraints driving a $10.9 million volume decline. Gross margin was 12.3%, broadly near the prior-year level, while the operating loss narrowed to $2.015 million and net loss improved materially to $5.133 million. The principal concern is liquidity: first-half operating cash flow was negative $27.520 million, and management explicitly reports substantial doubt about going concern unless the senior facility is refinanced before August 2027.

Read the original on SEC.gov

Gross and operating margin

How much of each revenue dollar the business keeps.

100% Gross margin Operating margin Apr 2026 Aug 2026

One point per quarterly or annual filing. Both margins are shares of that report's revenue.

From revenue to operating profit

Where each $100 of revenue went in this report.

Of every $100 of revenue Cost of sales $87 Operating expenses $15 Left as operating profit $-2

Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.

Where revenue came from

The business segments reported by the company.

Consolidated external net sales were 68.5% Q2 net sales by reported geography 31.5%

Shares of the segments disclosed in this filing, largest first.

How we read each report

Our analysis across the last few reports.

Read as bullish Read as bearish Apr 2026 Aug 2026

Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.

What stood out

  • Q2 operating loss narrowed by $0.615M

    Operating loss narrowed 23.4% to $2.015 million in Q2 2026 from $2.630 million a year earlier, as SG&A declined $0.780 million to $12.149 million.

  • Net loss improved by $15.125M YoY

    Net loss improved to $5.133 million from $20.258 million in Q2 2025, a $15.125 million reduction, helped by a sharply lower income-tax provision of $0.305 million versus $14.353 million.

  • EMEA reported sales rose 10.9%

    EMEA reported-sales growth was $5.435 million, or 10.9%, to $50.038 million in Q2. Management attributes $5.3 million of the increase to intercompany sales volume.

  • Credit facility maturity extended to 2027

    The April 2026 credit amendment extended the senior-credit-facility maturity by one year, from August 13, 2026 to August 13, 2027. The company reported $5.8 million of unused facility capacity, net of letters of credit, at June 30.

  • YTD operating loss improved $10.683M

    Six-month operating loss improved $10.683 million to $6.348 million from $17.031 million, primarily because prior-year results included $12.100 million of asset impairment expense.

What to watch

  • Going-concern doubt ahead of Aug. 2027 refinancing

    Management states substantial doubt about going concern because continued operations depend on refinancing the senior credit facility before its August 13, 2027 maturity. Cash was only $7.9 million and unused senior-facility capacity was $5.8 million at June 30, 2026.

  • Cash burn reached $27.520M in operating cash flow

    Operating cash flow swung to a $27.520 million outflow for the first six months of 2026 from $2.373 million of inflow a year earlier, driven by higher receivables, inventories and other current assets plus lower accounts payable. Investing outflows were another $16.682 million, primarily manufacturing and production-equipment capex.

  • Capacity constraints caused a $10.9M volume decline

    Q2 external net sales fell $7.148 million, or 7.3%, to $90.131 million. Management cites $10.9 million of volume-related declines, partly offset by $2.6 million in price/mix and $1.1 million of favorable FX; North America reported sales fell $5.628 million and Asia fell $3.383 million.

  • Restructuring had $17.697M of prior-year charges

    The Arkansas closure produced $17.697 million of restructuring-related charges in the first half of 2025, including $12.100 million of inventory write-offs. Management does not expect significant additional 2026 cash charges, but cautions it may not realize the anticipated cost savings and benefits.

  • No Item 1A update; macro costs remain exposed

    This smaller reporting company omitted Item 1A risk-factor disclosure in this 10-Q, so no formal risk-factor changes versus the prior filing were provided. The MD&A nevertheless identifies exposure to tariffs, supply-chain disruption, energy and commodity costs, and geopolitical conditions; Q2 gross profit fell $0.536 million to $11.098 million.

Management's outlook

The 10-Q provides no explicit quantitative revenue or EPS outlook. Management expects operating cash flow, cash on hand, and borrowing availability to meet requirements for the foreseeable future, but also states substantial doubt exists about going concern pending refinancing before the August 13, 2027 credit-facility maturity.

Earlier filings 2

10-Q · May 4, 2026

For Q1 2026, Viskase Holdings, Inc. reported a revenue decline of 8.1% to $86.5 million compared to $94.2 million in Q1 2025, mainly impacted by volume decreases in North America and despite a favorable foreign currency…

10-K · April 29, 2026

Enzon Pharmaceuticals, now known as Viskase Holdings, Inc., reported stagnant financial performance in its recent 10-K as it navigates significant structural changes following a merger and ultimate rebranding. Despite…

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.